Avidity Biosciences Inc
RNAM
Kedudukan dalam Saham
#2070
Avidity Biosciences, Inc. is at the forefront of developing a novel class of... Avidity Biosciences, Inc. is at the forefront of developing a novel class of oligonucleotide-based therapies, known as Antibody Oligonucleotide Conjugates (AOCs). Utilizing its proprietary AOC platform, the company engineers treatments that strategically merge the targeted delivery capabilities of monoclonal antibodies with the precise action of oligonucleotide-based therapeutics. This innovative method aims to reach cell and tissue types previously inaccessible to treatment, thereby more effectively addressing the fundamental genetic causes of various diseases. The company was established on November 13, 2012, by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick, and its main office is located in San Diego, California.
Harga Saham
$71.34
Disegerakkan terakhir: 2026-03-03
Modal Pasaran
$9.84B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-
Negara
US
Perdagangan Avidity Biosciences Inc (RNAM)
Kategori
Healthcare
Nisbah P/B bagi Avidity Biosciences Inc (RNAM)
Nisbah P/B pada October 2026 TTM: 6.44
Menurut laporan kewangan dan harga saham terkini Avidity Biosciences Inc, nisbah P/B semasa (TTM) ialah 6.44. Pada akhir 2024, nisbah P/B syarikat ialah 5.69.
Sejarah nisbah P/B untuk Avidity Biosciences Inc dari 2018 hingga 2026
Nisbah P/B pada akhir setiap tahun
| Tahun | Nisbah P/B | Ubah |
|---|---|---|
| 2026 (TTM) | 6.44 | 8.80% |
| 2025 | 5.92 | 4.15% |
| 2024 | 5.69 | -46.29% |
| 2023 | 10.59 | 61.58% |
| 2022 | 6.55 | -16.92% |
| 2021 | 7.89 | 53.53% |
| 2020 | 5.14 | -112.32% |
| 2019 | -41.71 | -37.04% |
| 2018 | -66.25 | 0.00% |
Nisbah P/B untuk syarikat atau pesaing yang serupa
| Syarikat | Nisbah P/B | Perbezaan Nisbah P/B | Negara |
|---|---|---|---|
| 6.6964 | 3.97% |
US
|
|
| 13.6307 | 111.63% |
US
|
|
| 4.4521 | -30.88% |
AU
|
|
| 4.2241 | -34.42% |
BE
|
|
| 6.3632 | -1.21% |
NL
|
